Becker's Healthcare September 12, 2024
Competition is brewing for Novo Nordisk and Eli Lilly, two of the world’s leading pharmaceutical weight loss companies, according to analysts.
Investment research company Morningstar and its subsidiary PitchBook, which analyzes global capital markets, published a report on GLP-1 competition in September.
Sixteen new obesity drugs are expected to launch between 2026 and 2029, accounting for about $70 billion of the GLP-1 market by 2031, according to the report. The market is also projected to reach $200 billion by 2031.
Three things to know:
1. In three to four years, experimental weight loss medications from several drugmakers could pressure drug...
Today's Sponsors
Today's Sponsor